AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2015
Jun 24, 2015
31523_dirs_2015-06-24_f3620b35-91d6-4936-aa06-8da068509dff.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-06-22
Reporting Person: Castelli Jeff (SVP, Program Management)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-06-22 | Common stock | M | 18981 | $13.9417 | Acquired | 43981 | Direct |
| 2015-06-22 | Common stock | S | 18981 | $13.9417 | Disposed | 25000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-06-22 | Stock Options (right to buy) | $2.52 | M | 1944 | Disposed | 2023-06-18 | Common Stock (1944) | Direct |
| 2015-06-22 | Stock Options (right to buy) | $3.53 | M | 6264 | Disposed | 2023-01-28 | Common Stock (6264) | Direct |
| 2015-06-22 | Stock Options (right to buy) | $4.16 | M | 10773 | Disposed | 2019-11-16 | Common Stock (10773) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.69 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.69 to $14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.